Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
Status:
Completed
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not
detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or
tertiary pattern 5, or final stage ≥ pT3a and/or pN1). Therefore this study evaluates the
ability of [68Ga]PSMA PET/MRI to detect and localize significant primary PCA to accurately
direct prostate needle biopsy using the Gleason score from the histology of the core biopsies
as standard of truth.